Selank is a seven-amino-acid synthetic peptide developed at the V.V. Zakusov Research Institute of Pharmacology in Moscow. The molecule is built on tuftsin (Thr-Lys-Pro-Arg), a four-amino-acid sequence with immunomodulatory activity, and extended with a Pro-Gly-Pro tail to slow down enzymatic breakdown.

Most of the laboratory work on Selank was done in Russia in the 2000s and 2010s, then expanded into English-language journals. The published literature is smaller than what you’ll find for BPC-157 or the GLP-1 family, but it’s specific: animal-model studies of monoaminergic and GABAergic signaling, with some work on neuropeptide expression patterns in cortical tissue.

The sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro. We supply it as a 5 mg lyophilized vial.

What you’ll find in the literature

Searching PubMed for “Selank” returns roughly 60 results in English. Most are out of Russian academic groups; a few are translated reviews. If you’re starting a literature scan from scratch, those translated reviews are usually the fastest entry point — they cite the original Russian papers and put the work in context for non-Russian-speaking labs.

Quality

Same standards as the rest of our catalog: HPLC for purity (target ≥99%), MS for identity, batch-specific Certificate of Analysis with every order. Lyophilized form is stable at 2–8 °C; reconstitute with bacteriostatic water and store the diluted solution at −20 °C for short-term use.

Compliance

Selank is supplied for laboratory research only. It is not approved by the FDA or any comparable regulatory authority for human or veterinary use, and is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. The order ships under our Research Use Only Disclaimer.

View the Selank 5mg product page →